We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Focused Ultrasound Therapy Shows Potential in the Noninvasive Treatment of Thyroid Nodules and Breast Fibroadenomas

By MedImaging International staff writers
Posted on 22 Oct 2013
Print article
Image: The Echopulse device, designed for ultrasound therapy (Photo courtesy of Theraclion).
Image: The Echopulse device, designed for ultrasound therapy (Photo courtesy of Theraclion).
A French medical company has reported very positive initial clinical findings from a new study on the treatment of thyroid nodules, demonstrating the effectiveness of its Echopulse device in the treatment of this disorder.

Trials for the treatment of benign thyroid nodules with echotherapy were conducted on 20 patients at the University Hospital of Endocrinology (Sofia, Bulgaria). The treatment reduced the size of the nodules in all patients. The reduction in size at the six-month mark was a median of 52%. These findings showed the effectiveness and excellent tolerance of ultrasound therapy for this disorder and were presented at the second edition of the Focused Ultrasound Symposium, held in Rome (Italy), on October 10 and 11, 2013. Theraclion (Malakoff, France), a company specializing in advanced medical equipment for ultrasound therapy, also known as echotherapy, is the developer of the Echopulse device.

A thyroid nodule is a protuberance that develops on the thyroid gland and is typically benign. Surgical intervention is the conventional treatment when a nodule is suspect, malignant, or benign but increases in size or causes physical discomfort for the patient. “These results with echotherapy are very encouraging. The significant reduction in nodule size at the end of six months, with a 94% reduction in some cases, demonstrates that the Echopulse can offer an alternative therapy that is less burdensome to the patient,” said Prof. Roussanka Kovatcheva, from the University Hospital of Endocrinology.

Moreover, new results from trials conducted in the treatment of breast fibroadenoma also confirm the effectiveness of the technology. This benign tumor is the most widespread (10% of women will develop it in the course of their lives) and accounts for more than half of benign breast tumors. These trials were performed on 42 patients in France, at the American Hospital of Paris, the Hospital of Valenciennes, and the University Hospital of Lille, and in Bulgaria, at the University Hospital of Endocrinology in Sofia. Treatment of 51 fibroadenomas treated with high-intensity focused ultrasound (HIFU) led to a 71% average reduction in tumor volume one year after the procedure. Also at the 12-month mark, 92% of patients showed a volume reduction of more than 60% and resolution of symptoms. The treatment reduced the size of fibroadenomas in all patients.

“We are very pleased with these encouraging primary results on thyroid nodules and the confirmation of the efficacy of Echopulse in the treatment of breast fibroadenoma. Our technology enables patricians to offer an effective, noninvasive, and scarless alternative to their patients,” said Stefano Vagliani, CEO of Theraclion.

Related Links:

Theraclion


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Color Doppler Ultrasound System
DRE Crystal 4PX
New
PACS Workstation
CHILI Web Viewer
New
Ultrasound Doppler System
Doppler BT-200

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.